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ABSTRACT 
KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies 
between cancers from different sites, but it is unclear whether allelic selection results from 
biological selection for specific mutant K-Ras proteins. We used a cross-disciplinary approach to 
compare K-RasG12D, a common mutant form, and K-RasA146T, a mutant that occurs only in selected 50 
cancers. Biochemical and structural studies demonstrated that K-RasA146T exhibits a marked 
extension of switch 1 away from the protein body and nucleotide binding site, which activates K-
Ras by promoting a high rate of intrinsic and GEF-induced nucleotide exchange. Using mice 
genetically engineered to express either allele, we found that K-RasG12D and K-RasA146T exhibit 
distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. 55 
These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating 
that context-dependent variations in signaling downstream of different K-Ras mutants drive the 
KRAS mutational pattern seen in cancer. 
 
SIGNIFICANCE: Although epidemiological and clinical studies have suggested allele-specific 60 
behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We 
combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the 
selection for specific K-Ras mutants in human cancers from different tissues is due to their distinct 
signaling properties.   
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INTRODUCTION 65 
Effective implementation of precision medicine requires a detailed understanding of the genetic, 
biochemical, biological, and clinical/epidemiological properties of cancer genes and their 
corresponding proteins. KRAS is the most frequently mutated oncogene in cancer. Its oncoprotein 
products, K-Ras4A and K-Ras4B, play an active role in tumor pathogenesis by engaging 
downstream signal transduction cascades to promote proliferation and survival. Efforts to target 70 
K-Ras and its effector signaling pathways have largely failed, making oncogenic K-Ras a major 
barrier to precision medicine for cancer. As a small GTPase, K-Ras activity is modulated by its 
nucleotide binding state. While wild-type (WT) K-Ras cycles between the GDP-bound (inactive) 
state and the GTP-bound (active) state with the help of guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs), somatic mutations found in cancer promote the 75 
GTP-bound state (1).  
K-Ras can be activated by missense mutation at any of a number of residues. Most cancer-
associated mutations occur at glycine 12 and these impair GAP-induced hydrolysis (2). Studies of 
genetically engineered mouse models have revealed that expression of K-RasG12D, the most 
common allele in human cancers, is sufficient to disrupt homeostasis in a variety of tissues (3-7). 80 
Some K-Ras mutations are restricted to certain tumor types. For example, alanine 146 (A146) is 
the fourth most common site of K-Ras mutation across all cancer types, but, A146 mutations are 
found almost exclusively in cancers of the intestinal tract and blood (8). Relative to other mutant 
forms of K-Ras, little is known about the biochemical and biological properties of K-Ras mutated 
at A146. A146V, the first mutant allele characterized, was originally identified through random 85 
mutagenesis almost three decades ago and was determined to alter H-Ras GTP binding affinity 
and to increase the rate of intrinsic nucleotide exchange (9). It was not until 2006 that A146 
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mutations (A146V and A146T) were identified as cancer-associated KRAS alleles (10,11). 
Although KRAS alleles are not typically differentiated in clinical practice, epidemiological studies 
suggest that cancers expressing different mutant forms of K-Ras exhibit distinct clinical behaviors 90 
(1,12). For example, in colorectal cancer (CRC) codon 146 mutations are associated with better 
overall survival relative to codon 12 mutations, however, like codon 12 mutants, they promote 
resistance to anti-Epidermal Growth Factor Receptor (EGFR) therapy (11,13,14). Whether the 
biological properties of K-Ras proteins activated through different biochemical mechanisms are 
similar or distinct, and whether distinct clinical behaviors derive from distinct biological properties 95 
of KRAS alleles, is unresolved. In this study, we undertook a comprehensive, multifaceted 
approach to systematically analyze the similarities and differences between mutant forms of K-
Ras in order to understand mechanisms driving allelic selection in cancer.  
 
RESULTS 100 
A146T promotes nucleotide exchange   
Missense mutations activate Ras proteins by altering their abilities to bind and/or hydrolyze GTP. 
To determine how mutation of codon 146 impacts the core biochemical properties of K-Ras, we 
first measured GDP dissociation +/- SOS1, a Ras GEF (15). We found that K-Ras4BA146T had a 
~12-fold higher rate of intrinsic GDP dissociation than K-Ras4BWT, which was further increased 105 
by addition of SOS1 (Fig. 1A,B). We noted that SOS1 stimulated exchange more effectively for 
K-Ras4BA146T than it did for K-Ras4BWT or K-Ras4BG12D and microscale thermophoresis 
demonstrated a roughly 100-fold increase in affinity of SOS1 for K-Ras4BA146T relative to WT 
protein (Fig. 1C). Next, we measured the rate of intrinsic and GAP-stimulated GTP hydrolysis. 
Intrinsic rates were similar between K-Ras4BA146T and K-Ras4BG12D, but reduced relative to K-110 
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Ras4BWT (Fig. 1D), while GAP-stimulated GTP hydrolysis was significantly impaired for K-
RasG12D, but only mildly impaired for K-Ras4BA146T (Fig. 1E). We also measured the affinity of 
K-Ras4B for its downstream effector RAF by using an AlphaScreen-based assay (16). All proteins 
exhibited similar binding affinity, indicating that in its GTP-bound form, K-Ras4BA146T assumes 
a more typical closed conformation that is able to engage RBD (Supplementary Fig. S1). These 115 
data are consistent with a model in which K-Ras4BA146T activation derives primarily from an 
increase in intrinsic and GEF-induced nucleotide exchange, not GAP insensitivity.  
 
Structural basis of rapid nucleotide exchange  
To understand the molecular basis for the increased basal and GEF-stimulated exchange rates of 120 
K-RasA146T, we solved a crystal structure of K-Ras4BA146T in complex with GDP (Supplementary 
Table 1). The structure is notable for a pronounced extension of switch 1 and β2 away from the 
body of the protein and nucleotide binding pocket (Fig. 2A, Supplementary Fig. S2). In most K-
Ras crystal structures, switch 1 participates in nucleotide binding, forming interactions with the 
base, sugar, and phosphates(17-19). Nevertheless, in the K-Ras4BA146T structure, the C-terminal 125 
region of the a1 helix undergoes a large conformational change, forming a new anti-parallel b 
interaction with what was originally b2 (now b3new in K-Ras4BA146T) and the usual b2-b3 
interaction is disrupted (Fig. 2A, Supplementary Fig. S2). In this position, switch 1 no longer 
participates in GDP binding. The active site is notable for loss of the magnesium ion (Fig. 2B), 
leading to alterations in switch 2 (Fig. 2A). Switch 1 destabilization appears to result from a new 130 
interaction with N7 of the purine base and sidechain oxygen of the mutated residue at Thr146 
which draws the guanine ring closer to residue 146 and slightly alters the pitch of the guanine base.  
In conjunction, the loop containing Thr146 is shifted towards a1, bringing Lys147 closer to the 
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base and enabling a new interaction between N3 of the base and the Lys147 side chain (Fig. 2B). 
Lys147 in this new position would be expected to clash with Phe28 in the closed switch 1 position. 135 
This clash and/or alterations in the nucleotide ring position destabilizes switch 1, releasing it to 
reorganize into the open conformation, leading to destabilization of switch 2 and loss of 
interactions with magnesium, which contributes to increased nucleotide dissociation.  
To confirm that this conformation is not an artifact of crystallization, we performed 
hydrogen-deuterium exchange mass spectrometry on K-Ras4BWT, K-Ras4BG12D, and K-140 
Ras4BA146T (Fig. 2C, Supplementary Figs. S3-S5). Consistent with an extended switch 1, K-
Ras4BA146T demonstrated increased rates of deuterium exchange (relative to K-Ras4BWT and K-
Ras4BG12D) in switch 1 and areas normally shielded by switch 1, such as the P loop (Fig. 2C). Of 
note, we also saw increased exchange in loops beneath the nucleotide ring, likely related to rapid 
nucleotide exchange.  145 
Similar to the K-Ras4BA146T:GDP structure, the SOS1:H-Ras co-crystal structure exhibits 
an extension of switch 1 away from the body of H-Ras (Fig. 2D), consistent with the role of SOS 
in catalyzing nucleotide exchange (20). The K-Ras4BA146T structure suggests that enhanced SOS1-
mediated GDP dissociation is related to altered switch 1 dynamics that enable interactions between 
SOS1 and K-RasA146T.  In short, these studies provide a structural mechanism for the increased 150 
rate of both intrinsic and GEF-induced nucleotide exchange seen for K-Ras4BA146T. 
 
Tissue-specific phenotypes of K-Ras alleles  
Distinct mechanisms of activation likely lead to differences in the steady state and kinetic levels 
of activated K-Ras in a cell, but it is difficult to predict whether this translates into distinct 155 
oncogenic behaviors. To study the contextual responses to K-Ras alleles activated by different 
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mechanisms, we generated a mouse strain carrying a Cre-inducible allele (KrasLSL-A146T) in the 
endogenous Kras locus (Supplementary Fig. S6A-D). This new mouse model – with the exception 
of the activating missense mutations – is identical to the extensively characterized KrasLSL-G12D 
allele (4,21), allowing us to directly compare the molecular and cellular effects of the two 160 
mutations.  
We first crossed KrasLSL-A146T mice to Fabp1-Cre mice, which express Cre recombinase in 
the colonic and distal small intestinal epithelia (22). We found that colons expressing K-RasA146T 
displayed moderate crypt hyperplasia that was intermediate between K-RasWT- and K-RasG12D-
expressing colonic epithelium (Fig. 3A-C). Using immunohistochemistry for phosphorylated 165 
histone H3 (PH3) to quantify crypt proliferation, we found that colons expressing K-RasA146T had 
an intermediate hyperproliferative phenotype compared to those expressing K-RasWT or K-RasG12D 
(Fig. 3D). Thus, compared to the strong effect that K-RasG12D has on basal colonic epithelial 
homeostasis, expression of K-RasA146T caused intermediate cellular and tissue-level phenotypes. 
To determine whether K-RasA146T could alter hematopoietic homeostasis, we crossed 170 
KrasLSL-A146T to the Mx1-Cre driver, which directs polyinosinic:polycytidylic acid (pI/pC)-
inducible Cre expression to hematopoietic stem cells (23). Induction of K-RasA146T led to 
myelodysplastic syndrome / myeloproliferative neoplasm (MDS/MPN) that was qualitatively 
similar to that induced by K-RasG12D mice, but with a significantly delayed onset. White blood cell 
counts slowly rose and hemoglobin levels declined over time in animals expressing K-RasA146T, 175 
with death occurring with severe anemia and splenomegaly at an older age than in animals 
expressing K-RasG12D (Fig. 3E,F and Supplementary Fig. 7A). Flow cytometry of tissues from 
moribund mice revealed that the end-stage phenotypes in animals expressing K-RasG12D and K-
RasA146T were similar, with expansion of immature myeloid cells in the bone marrow and spleen 
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(Supplementary Fig. 7B). We also tested whether K-RasA146T, like K-RasG12D, caused a cell-180 
intrinsic hyperproliferative phenotype in myeloid progenitor cells. K-RasA146T had only a modest 
effect on colony growth, with only a few spontaneous colonies and a nearly normal GM-CSF dose 
response (Fig. 3G).  
Although codon 146 mutations comprise ~10% of the KRAS mutations that occur in CRC, 
they rarely occur in other epithelial cancers, like pancreatic ductal adenocarcinoma (PDAC). To 185 
determine whether forced expression of K-RasA146T in the pancreas alters homeostasis, we crossed 
KrasLSL-A146T/+ mice to Pdx1-Cre mice, which express Cre recombinase in the developing pancreas 
(6). Unlike K-RasG12D, which promoted the development of pancreatic intraepithelial neoplasia 
(PanIN) by 8 weeks-of-age, pancreases expressing K-RasA146T did not exhibit any histologic 
evidence of PanIN at this age (Fig. 3H). We followed a cohort of Pdx1-Cre ; KrasLSL-A146T beyond  190 
2 months-of-age, including 4 animals beyond 300 days of age, and did not see any cases of PanIN. 
To determine whether acute pancreatitis could cooperate with K-RasA146T to promote PanIN, we 
treated animals with cerulein. Although this treatment accelerated the formation of PanIN in 
pancreases expressing K-RasG12D, it did not do the same in the context of K-RasA146T 
(Supplementary Fig. 8), indicating that this allele is not able to alter pancreatic homeostasis on its 195 
own.  
 
K-Ras cooperation in tumor models 
KRAS mutations do not drive cancer formation on their own, but rather cooperate with tumor 
suppressor gene mutations to promote malignant progression. As such, we posited that combining 200 
mutant K-Ras with appropriate secondary mutations might unmask the oncogenic potential of 
weak alleles like A146T. To explore this idea, we first crossed Fabp1-Cre carrying a KrasLSL allele 
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to those with a conditional allele of the Apc tumor suppressor gene, allowing us to determine the 
relative effects of K-RasA146T and K-RasG12D on colonic tumorigenesis. We found that colonic 
tumors expressing different K-Ras alleles shared common histologic features (Fig. 4A), but that 205 
they were significantly different in their abilities to reduce overall survival (Fig. 4B), just like in 
human CRC patients (11,13). The significant difference in survival among the different genotypes 
was likely due to a difference in the number of tumors, as the size of the tumors and the general 
histology – all were characterized as adenomas with low-grade dysplasia – were not significantly 
different (Supplementary Fig. S9A-B). 210 
Next, we crossed our two K-Ras alleles to Pdx1-Cre ; Tp53LSL-R270H/+ animals so that we 
could determine how each contributes to the development of pancreatic cancer. Interestingly, 9/12 
of the Pdx1-Cre ; Tp53LSL-R270H/+ animals expressing K-RasA146T developed pancreatic tumors, as 
did all of the controls expressing K-RasG12D (Fig. 4C). Although all of the cancers were invasive 
PDAC, the median lifespan of tumor-bearing mice expressing K-RasA146T was approximately 120 215 
days, which represented a significantly extended survival relative to animals expressing K-RasG12D 
(Fig. 4D). Together, our studies demonstrate for the first time that different mutant forms of K-
Ras exhibit distinct oncogenic properties that are tissue-specific and reflect the incidence of codon 
146 mutations in human cancer. 
 Allelic imbalance is reported to be common in cancers expressing mutant K-Ras and to play 220 
a key role in regulating the response to MAPK inhibition (24). To determine whether allelic 
imbalance plays a role in cancers expressing K-RasA146T, we first analyzed mutant and wild-type 
frequency in primary human cancers from the TCGA (25). Although we were able to identify 
cancers with KRAS allelic imbalance, we found no significant difference in the frequency of mutant 
or wild-type allele copy number variation when cancers were expressing KRASA146T or KRASG12D 225 
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(Supplementary Fig. 10A,B). We also measured KRAS copy number in human cancer cell lines 
and primary mouse tissues by droplet digital PCR (ddPCR). Most of the colon cancer cell lines we 
analyzed had two copies of KRAS, although LS1034, which expresses K-RasA146T, had multiple 
copies of the gene, as previously reported (11) (Supplementary Fig. 10C). Similarly, we found that 
the majority of mouse tumors from colon and pancreas carried just two copies of Kras 230 
(Supplementary Fig. 10D). The lone exception was a PDAC expressing K-RasA146T, which had 
four copies. In summary, it does not appear that allelic imbalance or amplification plays is required 
to enhance the tumorigenic properties of K-RasA146T.   
 
Global proteomic analysis of K-Ras alleles 235 
Since mutant K-Ras functions as the initiator of many different signal transduction cascades, we 
posited that the distinct in vivo oncogenic activities exhibited by mutant forms of K-Ras either 
derive from distinct signaling properties of the individual mutants themselves or from regulatory 
mechanisms incident to GAP- or GEF-mediated activation. To address this hypothesis, we 
performed multiplexed mass spectrometry on colons, pancreases, and spleens from mice 240 
expressing K-RasWT, K-RasG12D, or K-RasA146T to generate total proteome, phosphoproteome, and 
scaled phosphoproteome datasets, which normalize phosphopeptide levels to total protein levels 
(Fig. 5A, Supplementary Tables S2-S10). All tissues were collected from animals that were 
approximately 2-months-old. At this age, colons expressing mutant K-Ras are hyperplastic, but do 
not differ from wild-type in the proportions of epithelial cell types. For pancreases and spleens, 245 
there is likely to be some difference in cellular representation between wild-type and mutant tissues 
at this age. Principal component analysis (PCA) of data from each tissue revealed that allele 
replicates clustered together, but that different genotypes separated in principal component space 
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(Supplementary Figs. S11-S13). PCA of all of the collected data revealed two general aspects of 
signaling: (1) samples from the same tissue tended to cluster together regardless of Kras genotype 250 
and (2) samples expressing K-RasA146T tended to cluster closer to samples expressing K-RasWT 
than they did to samples expressing K-RasG12D (Supplementary Fig. S14).  
To uncover pathway-level biological insights from our MS data, we first used total protein 
data to perform gene-set enrichment analysis (GSEA) to identify Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways enriched in either K-RasA146T or K-RasG12D mutant tissues 255 
relative to WT. In the colon dataset, we found that proteins corresponding to many KEGG 
pathways were significantly enriched or de-enriched in colons expressing K-RasG12D or K-RasA146T 
relative to WT (Fig. 5B, Supplementary Table S11). Only two pathways were significantly (P < 
0.1 or FDR < 0.25) enriched in the presence of both K-Ras mutants (Fig. 5B). Importantly, we 
observed that the majority of the KEGG pathways analyzed were not coordinately regulated 260 
between the two K-Ras genotypes and several pathways were significantly affected in opposite 
directions by the two K-Ras mutants (Fig. 5B). Similar to the analysis of our colon dataset, GSEA 
applied to the pancreas dataset identified only a single KEGG pathway significantly enriched in 
the presence of both mutants (Fig. 5C, Supplementary Table S12). Similar to the colon, the 
majority of the KEGG pathways analyzed were discordantly regulated by the two K-Ras genotypes 265 
in pancreas and several pathways were significantly affected in opposite directions by the two K-
Ras mutations (Fig. 5C). Interestingly, KEGG_NITROGEN_METABOLISM, which was 
coordinately up-regulated by K-RasA146T and K-RasG12D in the colon, was coordinately down-
regulated in the pancreas (Fig. 5B,C). In spleen, K-RasG12D and K-RasA146T exhibited more similar 
signaling properties and there were no KEGG pathways that were discordantly regulated by the 270 
two mutant alleles relative to WT (Fig. 5D, Supplementary Table S13). In short, the two mutant 
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forms of K-Ras induced distinct downstream signaling effects that were strongly influenced by the 
tissue in which they were expressed. Importantly, although K-RasA146T is a weak mutant form of 
the oncoprotein, it significantly altered the proteome, even in pancreas, where it did not induce a 
histologic phenotype. 275 
When bound to GTP, K-Ras can directly bind to and activate downstream kinases. 
Additionally, multiple kinases regulate GEF or GAP activity and cells may utilize these 
mechanisms differentially in response to different modes of K-Ras activation (26,27). 
Nevertheless, it can be difficult to directly determine kinase activation state from MS data, 
especially when activating phosphorylation sites are not in the phosphopeptide dataset. To 280 
indirectly infer kinase activation downstream of mutant K-Ras within our scaled phospho-peptide 
dataset, we used an approach that combines the GSEA algorithm with custom ‘gene sets’ 
constructed of kinases and their confirmed substrates. Similar to our GSEA analysis of KEGG 
pathways, we found that there was differential activation of kinases induced by the two K-Ras 
genotypes in the three different tissues (Fig. 5E-G). In colon, there were more kinases predicted to 285 
be activated by K-RasA146T than by K-RasG12D. The only kinase predicted to be activated by both 
alleles was Erk2, although the substrates that contributed to enrichment were distinct in the two 
genotypes (Fig. 5E). There were fewer kinases identified in the pancreas dataset (Fig. 5F), 
presumably because the number of phosphorylation sites was smaller. As in our analysis of the 
total proteomes, the ability of the two K-Ras mutants to activate specific kinases was more similar 290 
in the spleen and there were no kinases that were predicted to be regulated in opposite directions 
(Fig. 5G). Of note, there was not a single pathway identified in the total proteome GSEA or the 
phosphoproteome SKAI that correlated, across all tissues, with the ability of mutant K-Ras to alter 
homeostasis. These results suggest that the signaling properties of K-Ras are allele- and tissue-
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specific and that mutant forms of K-Ras may be able to promote tumorigenesis through a variety 295 
of different signaling mechanisms. 
 
Allele-specific effects in human cancers  
We next sought to determine whether K-Ras  mutants were associated with distinct signaling 
properties in human cancers. We focused on CRC since it is the only cancer type in which the 300 
overall frequency of codon 146 mutation is high enough to provide statistical power to approach 
this question. Although there are published proteomic data from primary human CRCs, there are 
not enough codon 146 mutants in the dataset to perform a robust statistical analysis (28). Instead, 
we first performed multiplexed MS on a panel of CRC cell lines expressing different mutant alleles 
of KRAS (Supplementary Tables S14-S16). Here, we directly compared protein abundance or 305 
phosphorylation between cell lines comparing K-RasG12D or K-RasA146T and then compared the 
results to a similar analysis of our data from the mouse colon. Of the 6,279 proteins detected in 
both human and mouse datasets, we found that 156 (2.5%) were concordantly dysregulated 
between the two genotypes (Supplementary Fig. 15A, Supplementary Table S17). We found a 
similar pattern for 1,854 phosphopeptides that were detected in both human and mouse datasets, 310 
of which 306 (16.5%) were concordantly dysregulated (Supplementary Fig. 15A, Supplementary 
Table S17). This analysis demonstrates that there is a certain degree of allele-specific signaling 
that is conserved from mouse to human. 
Given that K-Ras signaling was conserved in cancer cell lines, we took this opportunity to 
ask whether the different mechanisms of activation of the K-Ras mutants translated into different 315 
responses to upstream perturbation even in the presence of a heterogeneous genetic background. 
SHP2 (encoded by the PTPN11 gene) is a phosphatase that functions upstream of Ras proteins by 
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controlling the activity of GEF (29). Since K-RasA146T is activated by virtue of increased intrinsic 
nucleotide exchange and is also sensitive to GEF-induced exchange, we explored whether SHP2 
inhibition would be more effective in the context of this mutant than when KRAS is wild-type or 320 
mutated at codon 12. On the contrary, cell lines expressing K-RasA146T were not more sensitive to 
SHP2 inhibition (Supplementary Fig. S15B), suggesting that the increase in intrinsic exchange is 
sufficient to drive the oncogenic properties of K-RasA146T. 
 In order to address the question of allele-specific molecular properties in primary human 
CRCs, we utilized gene expression data from the TCGA (25). When compared to cancers 325 
expressing WT K-Ras, cancers expressing K-RasG12D had numerous differentially expressed 
genes, however no obvious pattern was detected in the pathways or cellular processes affected 
(Supplementary Fig. 16A). For cancers expressing K-RasA146T, there were no genes differentially 
expressed relative to WT (Supplementary Fig. 16A). Thus, as in our proteomic analysis of mouse 
tissues, human cancers expressing K-RasA146T are more similar to WT than they are to cancers 330 
expressing K-RasG12D. 
 Human CRCs expressing different mutant forms of K-Ras appeared to be much less similar 
to one another than were tissues from genetically engineered mice and this is probably due to the 
fact that human cancers acquire many mutations that normalize the signaling networks between 
samples with distinct KRAS mutations. With this in mind, we hypothesized that if KRAS mutations 335 
arise early and confer distinct signaling properties on a developing cancer, then each allele might 
accumulate mutations in different sets of genes that will complement its specific oncogenic 
properties. Using available genome-wide mutation data from the TCGA CRC dataset, we asked 
whether cancers with different KRAS alleles accumulated mutations in similar or distinct 
secondary genes. Indeed, we identified 37 genes that were mutated specifically in the context of a 340 
  
 
15 
specific KRAS allele (Supplementary Fig. 16B). For example, PIK3CA, which encodes the p110a 
catalytic subunit of Phosphoinositide 3-kinase (PI3K), is statistically co-mutated with KRAS and 
this is largely due to its specific co-mutation with G12D alleles. There were more genes 
specifically mutated in the context of K-RasA146T (28) than K-RasG12D (10), however the overall 
number of mutations in cancers with different KRAS alleles was not different (Supplementary Fig. 345 
16B). There were no genes that co-mutated with both K-RasA146T and K-RasG12D.  The observation 
of distinct mutational profiles associated with different KRAS alleles supports a model in which 
mutant K-Ras proteins exhibit oncogenic properties that are allele-specific. 
 
Translation of signaling properties to tissue phenotypes 350 
Our next goals were to validate the results of our MS analysis and to understand how K-Ras allele 
signaling regulates cellular behaviors in the context of intact tissues. We focused on proteins that 
are known to function downstream of oncogenic Ras, as many of these appeared to vary between 
genotypes. For example, in our total protein analysis from colon, we detected a graded increase in 
Spred1 and Spred2, negative regulators of MAPK signaling, from WT to K-RasG12D and we were 355 
able to confirm allele-specific Spred2 up-regulation by western blotting (Supplementary Fig. 
17A,B). Moreover, GSEA analysis predicted up-regulation of p90Rsk activity in colons expressing 
K-RasA146T, but down-regulation in colons expressing K-RasG12D (Fig. 5E, Supplementary Fig. 
17C). Consistent with this prediction, we found that phosphorylation of ribosomal protein S6 on 
Ser240/Ser244 – a p90Rsk substrate – was down-regulated in colons expressing K-RasG12D 360 
(Supplementary Fig. 17D). Finally, GSEA identified negative enrichment for Akt1 substrates in 
colons expressing K-RasG12D and we confirmed by western blotting that phosphorylation of Akt 
on Ser473 – a readout of Akt activity – was reduced (Supplementary Fig. 17E,F).  
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Erk2 was the only kinase predicted by GSEA to be activated by both K-RasA146T and K-
RasG12D in the colon (Fig. 5E). We used quantitative western blotting to assess phosphorylation of 365 
Erk1/2 in colonic epithelia and found that colons expressing K-RasA146T and K-RasG12D exhibited 
higher levels of phosphorylated Erk1/2 than did WT colons, although K-RasG12D had a significantly 
stronger effect (Fig. 6A,B). Given the relatively low level of MAPK pathway activation in the 
context of K-RasA146T, we next evaluated whether, like K-RasG12D, it promotes hyperproliferation 
through MAPK signaling. Indeed, we found that inhibition of Mek with trametinib reduced the 370 
level of crypt proliferation in colons expressing K-RasG12D or K-RasA146T to the level of WT (Fig. 
6C), indicating that even low levels of MAPK signaling are sufficient to increase the rate of 
proliferation in this tissue.  
K-RasG12D also promotes proliferation in the small intestine, but its primary phenotypic 
manifestation in this tissue is inhibition of Paneth cell differentiation, which is due to MAPK 375 
activation (30). To determine the relationship between K-Ras genotype, MAPK signaling, and 
differentiation in the small intestinal epithelium, we measured Erk1/2 phosphorylation by 
quantitative western blotting and Paneth cell differentiation by staining for lysozyme. Similar to 
the colon, we found that K-RasA146T increased Erk1/2 phosphorylation, although not to the extent 
of K-RasG12D (Fig. 6D,E). Interestingly, we found that Paneth cells were intact in colons expressing 380 
K-RasA146T, but absent in colons expressing K-RasG12D (Fig. 6F). To confirm that the Paneth cell 
phenotype in animals expressing K-RasG12D is related to MAPK pathway activation, we treated 
animals with trametinib for four days and then performed immunofluorescence for lysozyme. We 
found that Paneth cell differentiation was restored in colons expressing K-RasG12D following Mek 
inhibition (Fig. 6F). These collective results suggest that different mutant forms of K-Ras produce 385 
different levels of MAPK signaling, which translate into both quantitatively and qualitatively 
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different phenotypes. Low-levels of MAPK activation cross the threshold required to alter 
proliferative kinetics, but a higher level of MAPK activation is required to cross the threshold 
required to interfere with differentiation. 
Since PanIN is a phenotype driven by defective differentiation induced by high MAPK 390 
signaling in the pancreatic duct (31), we explored whether K-RasA146T was unable to induce PanIN 
because its MAPK activation level is too low to affect differentiation. We noted from our MS data 
that the substrates downstream of Erk1/2 were differentially regulated by K-RasG12D and K-
RasA146T and, in particular, that Erk1/2 substrates were much more highly phosphorylated in colon 
and spleen than they were in pancreas (Supplementary Fig. S18). At the cellular level, while p-395 
Erk1/2 was essentially undetectable by immunohistochemistry in pancreatic ducts expressing K-
RasWT, it was highly expressed in the ducts and associated PanIN when K-RasG12D was expressed 
(Fig. 6G). Ducts expressing K-RasA146T exhibited detectable p-Erk1/2, but at a level much lower 
than that seen in ducts expressing K-RasG12D (Fig. 6G), suggesting that it fails to pass the MAPK 
threshold required to disrupt pancreatic homeostasis. 400 
 
DISCUSSION 
We have combined structural biology with mouse modeling and multiplexed MS to establish a 
new paradigm for oncoprotein signaling. We find that different mutant forms of K-Ras can have 
distinct biochemical mechanisms of activation that translate into distinct global signaling 405 
properties. Moreover, we have found that the ability of mutant K-Ras to impinge upon different 
aspects of tissue homeostasis (i.e. proliferation and differentiation) is dependent upon the absolute 
steady state level of MAPK activation, and thus the allele-specific signaling properties translate 
into allele-specific phenotypic manifestations. 
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Initially, our crystal structure of K-Ras4BA146T provided a molecular mechanism for the 410 
increased nucleotide exchange that defines A146T as an activating missense mutation (Figs. 1-2). 
This unique mechanism of activation translated into distinct in vivo oncogenic properties relative 
to K-RasG12D, which is activated by virtue of a defect in GTP hydrolysis, and these distinct 
oncogenic properties are the result of distinct allele-specific and tissue-specific signaling. In the 
intestinal epithelium and in blood, tissues where codon 146 mutations comprise a significant 415 
portion of KRAS alleles, K-RasA146T was able to disrupt basal homeostasis, although its effects 
were consistently weaker than those of K-RasG12D (Fig. 3). These graded effects are likely due to 
the different biochemical mechanisms of activation conferred by the G12D and A146T mutations 
(Fig. 1). K-RasG12D likely transmits a constant high-level signal to downstream pathways, while 
K-RasA146T, because of its reduced affinity to nucleotide, likely transmits an unstable weak 420 
downstream signal. This hypothesis is supported by our analysis of MAPK signaling in the 
intestinal epithelia, which demonstrated that the steady state level of pathway activation is higher 
in colons expressing K-RasG12D than in colonic and small intestinal epithelia expressing K-RasA146T 
(Fig. 6A-B,D-E). This gradient of MAPK pathway activation (WT < A146T < G12D) produced a 
proportional proliferative response in the colonic epithelium (Fig. 3D, 6C). The effect of mutant 425 
K-Ras on differentiation was not proportional, however, as mice expressing K-RasG12D lacked 
Paneth cells in the small intestine because of high MAPK signaling, while K-RasA146T-expressing 
mice had intact Paneth cells (Fig. 6F). These observations suggest that the MAPK threshold for 
inhibition of differentiation is higher than the threshold for promoting proliferation. Consistent 
with this model, K-RasA146T exhibited relatively low MAPK activation in the pancreas and did not 430 
induce PanIN (Fig. 3H, 6G), a phenotype that requires dysregulation of differentiation. 
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Our global analysis of allele- and tissue-specific signaling of mutant forms of K-Ras 
highlights the complex nature of signaling pathways, with MAPK serving as a prime example. 
Erk2 was predicted to be activated by both mutant forms of K-Ras in both colon and spleen, 
however the kinase-substrate relationships were not consistent across these contexts. In colon, the 435 
majority of Erk2 substrates that were up-regulated in mutant tissue relative to WT were specific to 
one allele (Fig. 5E). In the spleen, the substrate patterns of the two alleles were similar, and they 
resembled the pattern seen in colons expressing K-RasA146T (Fig. 5G). Another example 
demonstrating that the MAPK output from each K-Ras allele is distinct is exemplified by p90Rsk 
substrates. We observed that phosphorylation of p90Rsk substrates was up-regulated in colons 440 
expressing K-RasA146T, but down-regulated in colons expressing K-RasG12D (Fig. 5E). This 
observation suggests that K-RasG12D induces a previously unrecognized feedback loop at the level 
of p90Rsk, downstream of Erk. The differential activity of p90Rsk itself could also exert a negative 
feedback onto MAPK signaling through phosphorylation of SOS1 (a Ras GEF) on Ser1134 and 
Ser1161, which allows binding of 14-3-3 and disrupts signaling from receptor tyrosine kinases to 445 
Ras (32). Of note, we detected differential phosphorylation of Ser1120 (the mouse Ser1134 
equivalent) on Sos1 by K-RasA146T and K-RasG12D (Fig. 5E). This result suggests that this negative 
feedback mechanism might be disrupted in K-RasG12D-mutant tissue, which could contribute to 
sustained MAPK signaling, or could be up-regulated by K-RasA146T to confer some advantage in 
cellular fitness. These observations suggest that pathway activation can assume many forms and 450 
that the ultimate functional output of a pathway is not dependent upon activation of a single 
component, but by the cumulative effects of pathway flux and feedback mechanisms. 
While our studies focus specifically on K-Ras, the results illustrate a number of general 
principles that will relate to other oncogenes. First, variations in the biological properties of distinct 
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alleles of the same oncogene can explain, at least in part, the tissue-specific mutational profiles 455 
seen in human cancers. Next, even in tissues where distinct alleles have oncogenic phenotypes, 
different biochemical mechanisms of oncoprotein activation can lead to profound differences in 
signaling. Since the phenotypic output of an activated oncoprotein depends on the state of the 
cellular signaling network as a whole, distinct alleles can produce different phenotypes. The 
implication of this paradigm is that different mutant forms oncoproteins can make equivalent 460 
functional contributions to cancer initiation and progression, yet have allele-specific therapeutic 
vulnerabilities in downstream effector pathways. The combination of structural biology, mouse 
genetics, and global signaling analysis deepens our understanding of how the oncogenic output of 
K-Ras relates to its biochemical mechanism of activation and provides the first demonstration that 
tissue-specific allelic selection is driven by the distinct signaling properties of mutant K-Ras 465 
alleles. 
 
METHODS 
Hydrogen Deuterium Exchange Mass Spectrometry (HDX MS) 
HDX MS experiments were performed similarly to previous reports (16,33). For comparison 470 
between WT and A146T, proteins were diluted into sample buffer (10 mM HEPES pH 8.0, 5 mM 
MgCl2, 5 µM GDP, 150 mM NaCl) to a concentration of 10 µM prior to labeling. Samples were 
independently labeled with deuterium in duplicate, using identical experimental conditions to 
allow direct comparisons between K-Ras WT and A146T. HDX was initiated by diluting 2.0 µl of 
protein sample (10 mM HEPES, pH 8.0, 5 mM MgCl2, 5 µM GDP, 150 mM NaCl) 18-fold in 475 
labeling buffer (10 mM HEPES, pH 8.0, 5 mM MgCl2, 5 µM GDP, 150 mM NaCl) containing 
99% deuterium oxide at room temperature. The labeling reaction was quenched at six time points 
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(5 s, 10 s, 1 m, 10 m, 1 h, 4 h) through the addition of 38.0 µl quench buffer (300 mM sodium 
phosphate, pH 2.47) at 0°C. For experiments comparing WT and G12D, protein sample buffer (20 
mM HEPES pH 7.5, 150 mM NaCl), labeling buffer (20 mM HEPES pH 7.5, 150 mM NaCl), and 480 
quench buffer (0.8%FA; 0.8M GdnHCl; pH 2.4) were slightly different than in the A146T 
experiment. Quenched samples were immediately analyzed. Deuterium measurement with MS 
was performed as previously described (16,33) using a Synapt G2si HDMSE, online digestion 
Enzymate column, 1x50 1.8 µm HSS T3 separation, 1.7 µm BEH trap. Deuterium incorporation 
graphs (Supplementary Fig. S4,S5) were generated using DynamX 3.0 software (Waters) by 485 
subtracting the centroid of the isotopic distribution at each labeling time point from the centroid 
of the isotopic distribution of the undeuterated reference species. Since the data were not corrected 
for back-exchange, each data point represents the relative deuterium level at each time point for 
each peptide (34).  
 490 
GTPase Activity Assay 
Intrinsic and GAP-stimulated GTPase activity for WT and mutant K-Ras4B proteins were 
measured using EnzCheck phosphate assay system (Life Technologies) as previously described 
(17). In brief, K-Ras4B proteins (2.5 mg/ml) in buffer (20 mmol/L Tris pH 8.0, 50 mM NaCl) 
were loaded with GTP at RT for 2 hours by exposing to exchange buffer containing EDTA. 495 
Proteins were buffer exchanged to assay buffer (30 mmol/L Tris pH 7.5, 1 mmol/L DTT) and the 
concentration adjusted to 2 mg/ml. GTP loading was verified by back extraction of nucleotide 
using 6M urea and evaluation of nucleotide peaks by HPLC using an ion-exchange column as 
described previously (33). The assay was performed in a clear 384-well plate (Costar) by 
combining GTP-loaded K-Ras4B proteins (50 µM final) with MESG (200 µM final), and purine 500 
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nucleotide phosphorylase (5 U/ml final). GTP hydrolysis was initiated by the addition of MgCl2 
at a working concentration of 40 µM. For GAP stimulation P120GAP was included at 50 µM. 
Absorbance at 360 nm was read every 8 to 15 seconds for 3600 seconds at 20oC. All measurements 
were performed in triplicate. 
 505 
Nucleotide Dissociation Assay 
Nucleotide dissociation reactions were performed using a fluorescent guanine nucleotide analogue 
(Mant-GTP) that shifts absorbance when bound to Ras (15). K-Ras4B proteins (100 µM) were 
loaded with Mant-GDP by incubating with 300 µM Mant-GDP and 5 mM EDTA in PBS at 25°C 
for 2 hours. Reactions were terminated with 10 mM MgCl2, and then buffer was exchanged to 510 
remove EDTA and unbound nucleotides by using 2 mL Zeba™ (ThermoFisher Scientific) 
desalting cartridges (7,000 Da MWCO) into buffer PBS supplemented with 2 mM MgCl2 and 1 
mM EDTA. Reactions were started by mixing RAS and other reagents using a two channel 
injection system mounted on a Synergy Neo reader (BioTek). Fluorescence was measured every 
0.5 seconds for 5 minutes at 360nm/440nm (excitation/emission) in a 384-well plate at ambient 515 
temperature. Final reaction conditions for intrinsic dissociation (K-Ras4B alone) were 2 µM K-
Ras4B, 4 µM GDP in PBS with 2 mM MgCl2, 1 mM EDTA. Final reaction conditions for SOS-
mediated dissociation were 2 µM K-Ras4B, 4 µM GDP, 2 µM SOS1 in the same buffer. Data were 
exported and analyzed using Prism 7 (GraphPad Software, Inc.). All measurements were 
performed in triplicate. 520 
 
Microscale Thermophoresis (MST)  
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K-Ras4B proteins (130 µM) in 1X PBS and 200 µM GDP were incubated at room temperature for 
1hr.  The solution was then desalted into 1X PBS with 2 mM MgCl2 and 1% tween 20 via a Zeba™ 
(Thermo Fisher) spin desalting column. 16-point serial dilutions of K-Ras4B were prepared and 525 
mixed 1:1 with GFP-556SOS1049 in final volume of 20 µL. The reaction mixtures were loaded into 
premium treated capillaries and analyzed by a Monolith NT.115 (Nanotemper Technologies) at 
40% MST power and 40% LED power with a laser-on time of 30 s. The KD was calculated by 
taking the average of duplicate Fnorm measurements at each concentration and fitting the data by 
using Palmist (35) and plotting in Prism 7. 530 
 
RAF Interaction Assay 
K-Ras4B:RAF kinase interaction assays were performed as previously described (16). Purified 
RAF-1 RBD was labeled with maleimide PEG biotin (Pierce) following the manufacturer's 
recommended protocol. Purified flag-tagged K-Ras4B (1 mg/mL) were loaded with GMPPNP 535 
(Sigma-Aldrich) by incubating for 2 hours at 25°C with a 50-fold excess of nucleotide in the 
presence of alkaline phosphatase (Thermo-Fisher). RAF–RBD–biotin was diluted to a final 
concentration of 40 nM and Flag-K-Ras4B to 10 nM in assay buffer (20 mM Tris pH 7.5, 100 mM 
NaCl, 1 mM MgCl2, 5% glycerol, 0.5% BSA) and added to individual wells of a low-volume white 
384-well plate (PerkinElmer). Complexes were disrupted by addition of a dilution series (2,000 540 
nM to 0.5 nM) of each mutant K-Ras4B protein. The assay was developed by addition of 
streptavidin donor and anti-flag acceptor AlphaScreen beads (10 µg/mL). Alpha signal was 
measured after overnight incubation at 4°C. All readings were performed in triplicate. 
 
Structure Determination and Refinement 545 
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K-Ras4BA146T protein was concentrated to 13 mg/ml prior to crystallization trials using an 
Amicon® Ultra Centrifugal Filter with a molecular weight cutoff of 10,000 Daltons. Single protein 
crystals were grown using hanging drop vapor diffusion at 20°C from a reservoir solution 
containing 1.4 M sodium malonate pH 7.0, 0.1 M BIS-TRIS propane pH 7.0. Prior to diffraction 
crystals were soaked briefly in cryo-protectant containing reservoir solution supplemented with 550 
25% (v/v) glycerol. X-ray diffraction data was collected at the Advanced Photon Source beamline 
19-ID at 100K. The initial diffraction data were indexed, integrated, and scaled using HKL2000. 
The K-Ras4BA146T:GDP crystal structure was determined by molecular replacement using wild-
type (WT) K-Ras4B (PDB entry 4OBE) as an initial search model with Phaser in the CCP4 Suite 
(36). The model was further built and refined using Phenix (37) and COOT (38) by manual model 555 
correction. Waters were added and the final refinement performed by Phenix Phenixrefine (37). 
Stereochemical parameters of the final model were analyzed with the assistance of Molprobity 
(39). Data collection and refinement statistics are listed in Supplementary Table S1.  
 
Animal Studies 560 
Animal studies were approved by the Institutional Care and Use Committee at Massachusetts 
General Hospital, Beth Israel Deaconess Medical Center, and the University of California, San 
Francisco. Mice were fed ad libitum and housed in a barrier facility with a temperature-controlled 
environment and twelve-hour light/dark cycle. Pdx1-Cre and Mx1-Cre mice were obtained from 
The Jackson Laboratory (Strain No. 014647). Fabp1-Cre (Strain 01XD8), Apc2lox14 (Strain 565 
01XP3), K-RasLSL-G12D (Strain 01XJ6), and Tp53LSL-R270H (Strain 01XM1) mice were obtained from 
the NCI Mouse Repository. Experimental animals  were maintained on genetic background that 
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was 80-95% C57BL/6. Survival curves for tumor-bearing animals were analyzed using log-rank 
test (Prism 7). 
The KrasLSL-A146T-Neo allele was generated in TL1 embryonic stem (ES) cells (129/Sv 570 
genetic background) (40). Using embryonic stem (ES) cells with a transcriptional stop element 
(lox-stop-lox, LSL) inserted into the endogenous Kras locus (KrasLSL-WT), we engineered an 
alanine to threonine mutation at codon 146 in exon 4 to generate KrasLSL-A146T mice. ES cells were 
injected into C57BL/6J embryos in the Harvard Medical School Transgenic Mouse Core and 
chimeric males were backcrossed to C57BL/6 females. The PGK-Neo selection cassette was 575 
deleted from the Kras locus by crossing KrasLSL-A146T-Neo mice to a Flp deleter strain (Jackson 
Laboratory, stock number 007844). The KrasLSL-A146T allele was subsequently maintained in a 
primarily C57BL/6 background by continuous backcrossing. Age-matched Fabp1-Cre or Pdx1-
Cre littermates were used as K-Ras WT controls in all experiments. For experiments analyzing 
coon and pancreas, all animals were 8-12 weeks-of-age. For analysis of hematopoietic phenotypes, 580 
mice were maintained in a C57BL/6 ´ 129SvJae F1 background. Mx1-Cre was induced by i.p. 
injection with 250 µg polyinosinic-polycytidylic acid (pIpC) at four weeks. Peripheral blood 
counts were measured using a Hemavet 950FS instrument (Drew Scientific). Serial white blood 
cell counts were analyzed as described in (41).  
 585 
Tissue Staining, IHC, and IF 
Tissue was harvested from mice, fixed in 10% formalin overnight at room temperature, and 
processed into paraffin blocks. Tissue sections (5 µm) were deparaffinized in a standard xylene 
and ethanol series. Standard H&E staining protocols were used. Histology of colon and pancreas 
was review by a board-certified gastrointestinal pathologist (Dr. Nowak). For crypt height 590 
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analyses, crypts were measured using Olympus VS-ASW version 2.7 software as described in 
(42). 
For IHC, deparaffinized sections were subjected to antigen retrieval in a pressure cooker 
in Target Retrieval Solution, pH 6 (DAKO®). IHC was performed using the EnVision+ HRP Kit 
(DAKO®). Images were acquired using an Olympus BX-UCB slide scanner. Primary antibodies 595 
were diluted in Antibody Diluent (DAKO®) and incubated overnight at 4°C. For IF, following 
antigen retrieval, sections were incubated in Protein Block, Serum-Free (DAKO®) for twenty 
minutes at room temperature. Primary antibodies were diluted in Antibody Diluent (DAKO®) and 
incubated overnight at 4°C. Slides were then washed in PBS, and secondary antibodies diluted in 
Antibody Diluent were filtered through 0.45 µM filters (Millipore), and incubated for one hour at 600 
room temperature in the dark. Coverslips were mounted using ProLong® Diamond with DAPI 
(Thermo Fisher) and images were acquired using a Zeiss Axio Imager Z2. Primary antibodies 
included: anti-phospho-histone-H3 (Ser10; CST), anti-E-cadherin (BD), anti-b-catenin (CST), and 
anti-lysozyme (Thermo). Fluorescent secondary antibodies included: anti-mouse IgG2a Alexa 
Fluor 488 (ThermoFisher) and anti-rabbit Alexa Fluor 594 (ThermoFisher). Proliferation results 605 
were analyzed using Mann-Whitney U tests (Prism 7). 
 
Western Blotting 
Tissue was harvested from mice and flash frozen in liquid nitrogen immediately. Tissue was lysed 
in Bio-Plex® Lysis Buffer (Bio-Rad) supplemented with Factor I, Factor II, PSMF (2 nM), and 610 
cOmplete™ protease inhibitor cocktail (Sigma-Aldrich), or Mg2+ Lysis/Wash Buffer (Millipore), 
supplemented with cOmplete™ protease inhibitor cocktail (Sigma-Aldrich) and phosphatase 
inhibitor cocktails 2 and 3 (Sigma). Following clearing by centrifugation, protein lysates were 
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quantified using a bicinchoninic acid assay (BCA, Pierce) and samples were equally loaded for 
SDS-PAGE. Western blotting was performed according to standard protocols and analysis was 615 
performed on an Odyssey® CLx Infrared Imaging System (LI-COR®). Western blot images were 
quantified using Image Studio Software (LI-COR®). Primary antibodies included: anti-Ras 
(Millipore, 05-516), anti-a-tubulin (Sigma, T6074), anti-p-Erk1/2 (Thr202/Tyr204; Cell Signaling 
Technologies [CST], 4377), anti-Erk1/2 (CST, 4696), anti-GAPDH (CST, 5174), anti-p-Akt 
(Ser473; CST, 4060), anti-Akt (CST, 9272), and anti-pS6 (Ser240/244; CST, 5364). Secondary 620 
antibodies included: anti-mouse IgG Alexa Fluor 680 (ThermoFisher, A21058) and anti-rabbit IgG 
Alexa Fluor 800 (ThermoFisher, A32735). Western blot results were analyzed using Mann-
Whitney U tests (Prism 7). 
 
Inhibitor and Cerulein Treatments 625 
For analysis of proliferation, 8–12-week-old mice were treated once every 12 h for 24 h with 0.25 
mg/kg trametinib or 10% DMSO vehicle. For analysis of Paneth cell differentiation, 8-12 week 
old mice were administered 1 mg/kg trametinib twice per day for four days or 4% DMSO in corn 
oil. For cerulein treatment, 8–12-week-old mice were treated with 250 µg/kg cerulein (in normal 
saline, 0.9% NaCl) or with normal saline vehicle once daily for five days. Mice were sacrificed 630 
and tissues were harvested 30–31 days after the first treatment.  
 
Mass Spectrometry 
Mouse tissues or human cell line pellets were homogenized using a polytron at medium speed 
followed by 10 passes through a 21-gauge needle in 100 mM EPPS, 8 M Urea, pH 8.5, 635 
supplemented with 1X cOmplete™ protease inhibitor cocktail (Sigma-Aldrich) and 1X PhosSTOP 
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phosphatase inhibitors (Sigma-Aldrich). The homogenate was sedimented at 21,000 x g for 5 min 
and the supernatant was transferred to a new tube. Protein concentrations were determined using 
a BCA assay (ThermoFisher Scientific). Proteins were subjected to disulfide bond reduction with 
5 mM Tris (2-carboxyethyl)phosphine (room temperature, 30 min) and alkylation with 10 mM 640 
iodoacetamide (room temperature, 30 min in the dark). Excess iodoacetamide was quenched with 
10 mM dithiotreitol (room temperature, 15 min in the dark). Methanol-chloroform precipitation 
was performed prior to protease digestion. Four parts of neat methanol were added to each sample 
and vortexed, one part chloroform was added to the sample and vortexed, and three parts water 
was added to the sample and vortexed. The sample was centrifuged at 14,000 RPM for 2 min at 645 
room temperature and washed twice with 100% methanol. Samples were resuspended in 200 mM 
EPPS, pH 8.5, and digested at room temperature for 13 h with Lys-C protease at a 100:1 protein-
to-protease ratio. Trypsin was then added at a 100:1 protein-to-protease ratio and the reaction was 
incubated for 6 h at 37°C. Phosphopeptides were enriched following digestion and prior to TMT 
labeling using a method based on that of Kettenbach and Gerber and described elsewhere (43,44). 650 
TMT and Off-line Basic pH Reversed-phase Fractionation were performed as previously described 
in (44). 
 All samples were analyzed on an Orbitrap Fusion Lumos mass spectrometer (Thermo 
Fisher Scientific, San Jose, CA) coupled to a Proxeon EASY-nLC 1200 liquid chromatography 
pump (Thermo Fisher Scientific). Peptides were separated on a 100 µM inner diameter 655 
microcapillary column packed with 35 cm of Accucore C18 resin (2.6 µM, 150 Å, ThermoFisher). 
For each analysis, we loaded approximately 2 µg onto the column. For whole proteome analysis, 
peptides were separated using a 180 min gradient of 3-25% acetonitrile in 0.125% formic acid 
with a flow rate of 450 nL/min. Each analysis used an MS3-based TMT method (45). The scan 
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sequence began with an MS1 spectrum (Orbitrap analysis, resolution 120,000, 400−1,400 Th, 660 
automatic gain control [AGC] target 5E5, maximum injection time 100 ms). The top ten precursors 
were then selected for MS2/MS3 analysis. MS2 analysis consisted of: collision-induced 
dissociation, quadrupole ion trap analysis, AGC 2E4, normalized collision energy (NCE) 35, q-
value 0.25, maximum injection time 120 ms), and isolation window at 0.7. Following acquisition 
of each MS2 spectrum, we collected an MS3 spectrum in which multiple MS2 fragment ions are 665 
captured in the MS3 precursor population using isolation waveforms with multiple frequency 
notches (45). MS3 precursors were fragmented by HCD and analyzed using the Orbitrap (NCE 
55, AGC 2.5E5, maximum injection time 120 ms, resolution was 60,000 at 400 Th). For MS3 
analysis, we used charge state-dependent isolation windows: for charge state z=2, the isolation 
window was set at 1.3 Th, for z=3 at 1 Th, for z=4 at 0.8 Th, and for z=5-6 at 0.7 Th. 670 
Likewise, for phospho-proteome analysis, peptides were separated using a 120 min 
gradient. The scan sequence began with an MS1 spectrum (Orbitrap analysis, resolution 120,000, 
400−1400 Th, AGC target 5E5, maximum injection time 100 ms). The top ten precursors were 
then selected for MS2/MS3 analysis. MS2 analysis consisted of the following: collision-induced 
dissociation, quadrupole ion trap analysis, AGC 2E4, NCE 35, q-value 0.25, maximum injection 675 
time 120 ms), and isolation window at 0.7. Following acquisition of each MS2 spectrum, we 
collected an MS3 spectrum in which multiple MS2 fragment ions are captured in the MS3 
precursor population using isolation waveforms with multiple frequency notches (45). MS3 
precursors were fragmented by HCD and analyzed using the Orbitrap (NCE 55, AGC 3E5, 
maximum injection time 300 ms, resolution was 60,000 at 400 Th). For MS3 analysis, we used 680 
charge state-dependent isolation windows: for all charge states, the isolation window was set at 
1.2 Th.  
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LC-MS3 Analysis 
Mass spectra were processed using a Sequest-based in-house software pipeline (46). Data analysis 685 
was performed as previously described in (44,47). Proteins and phosphopeptides were quantified 
by summing reporter ion counts across all matching PSMs using in-house software, as described 
previously (46). PSMs with poor quality, MS3 spectra with at least one TMT reporter ion channels 
missing, MS3 spectra with TMT reporter summed signal-to-noise ratio that were less than 100, or 
had no MS3 spectra were excluded from quantification (48). Each reporter ion channel was 690 
summed across all quantified proteins and normalized assuming equal protein loading of all 10 
samples across the TMT10-plex. Protein quantification values were exported for further analysis 
as described below. 
Scaled phosphopeptides were calculated as a composite ratio of a phosphopeptide and the 
corresponding total protein value where possible. UniProt IDs were used as the identifier to match 695 
phosphopeptides with their protein value. 
 
Analysis of MS Data 
GSEA was conducted on the protein dataset. KEGG pathway gene sets were downloaded from 
MSigDB [GSEA, KEGG1, KEGG2, KEGG3, MSIGDB]. To uniquely identify proteins within our 700 
dataset, gene symbols were converted to murine UniProt IDs by programmatically accessing the 
ID mapping tool (http://www.uniprot.org/mapping/), retaining both reviewed and unreviewed 
matches. GSEA was run using a pre-ranked list of genes. The ranking metric used is listed below, 
a non-parametric signal-to-noise value, 𝑚" −	𝑚%𝑀𝐴𝐷" +	𝑀𝐴𝐷% 705 
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where m is the median and MAD is the median absolute deviation when comparing groups A 
versus B (either G12D versus WT or A146T versus WT). 𝑀𝐴𝐷 has a minimum value of 0.2 * |	𝑚|. 
Additional parameters used in the analysis can be found in Data S10-S12. Pathways presented 
were considered enriched if the enrichment of their substrate set surpassed a threshold of either a 
nominal p-value < 0.1 or an FDR-q value < 0.25.  To visualize results from each comparison, we 710 
performed hierarchical clustering as above. 
For inference of kinase activity, we performed GSEA on phospho-proteomic data with 
custom gene sets constructed of kinases and their respective species-specific substrate sites, termed 
substrate site sets, assembled from datasets available from PhosphoSite (49). A pre-ranked 
enrichment was conducted as described above, using scaled phospho-peptide data.  Kinases were 715 
considered significantly active if the enrichment of their substrate set surpassed a threshold of 
either a nominal p-value < 0.1 or an FDR-q value < 0.25.  Results from each comparison were 
clustered via hierarchical clustering as above. 
 
Droplet Digital PCR (ddPCR) 720 
Genomic DNA was extracted from snap frozen or formalin-fixed paraffin-embedded cell pellets 
or mouse tissues using QIAGEN DNeasy Blood and Tissue Kit or QIAamp DNA FFPE Tissue 
Kit. ddPCR was carried out according to Bio-Rad’s protocol. In brief, 100 ng of sample DNA was 
digested with HaeIII at 37°C for 1 hour and added to a PCR reaction master mix containing 2x 
ddPCR Master Mix (Bio-Rad), 20x target assay mix, and 20x reference assay mix, both made with 725 
forward and reverse primers, hybridization probe, and water. Droplets were generated on Biorad’s 
QX200 with droplet generation oil, subject to amplification (95°C 10 min, 94°C 30 sec, 59°C 1 
min, repeated 40x, 98°C 10 min, 8°C hold), and read on Bio-Rad’s QX200 Droplet Reader running 
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QuantaSoft software. Copy number (CN) was calculated using the following equations, 
concentration = -ln(# negative droplet / # total droplets), CN = (target concentration / reference 730 
concentration) * # copies of reference in genome. Mouse Kras was amplified with primers 5’- 
AGCAAGGAGTTACGGGATTC-3’ and 5’- TGCCATCAGGAAATGAAGAT-3’ with 
hybridization probe 5’- FAM-TGCTCCAGATGGTGTTCGTCA-Black Hole Quencher-3’, while 
the reference gene (Xist) was amplified with 5’- TGTTTGAACTCCCAGACCTCTT -3’ and 5’- 
AGGACATTCAGGCAAAAGAAAA-3’ with hybridization probe 5’-HEX-735 
CAACCTGGCTCCATCTTCTCTGTTCC-Black Hole Quencher-3’. Mouse oligonucleotides 
were ordered from IDT. Human KRAS copy number was detected with Bio-Rad’s validated copy 
number assay mix (dHsaCP2507077, HEX) with reference RPP30 (dHsaCP1000485, FAM).  
 
SHP2 inhibition in cell lines 740 
DiFi cells were a gift from Robert Coffey (Vanderbilt University), CCCL18 and HCC2998 were 
provided by David Solit (Memorial Sloan Kettering Cancer Center), and the remaining cell lines 
were purchased from ATCC. Cell lines were validated by STR profiling and screened for 
mycoplasma by Genetica . 
All cells were cultured in recommended media at 37°C, 5% CO2. SHP099 (ChemieTek) 745 
was dissolved in DMSO to 10 mM for storage. The day before drug treatment, 4000-6000 cells 
per well were plated in 96-well plates in 100 µL of complete media, including a plate with all cell 
lines for day 0 readout for GR value calculations (day 0 plate). The next day (day 0), SHP099 was 
serially diluted in culture media in the range of 2 nM - 100 µM and 100 µL of drug dilution added 
to respective wells, resulting in a final drug concentration range of 1 nM – 50 µM. DMSO-only 750 
wells received 2% DMSO in culture media. 100 µL of regular culture media was added to the day 
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0 plate, which was returned to 37°C to equilibrate before adding MTT (Sigma) to determine 
baseline viability. Drug-treated plates were cultured at 37°C, 5% CO2 for 72 hours and cell 
viability determined with the MTT assay. GR values were calculated from absorbance values with 
the online tool GR Calculator (http://www.grcalculator.org/grcalculator/) and graphs generated by 755 
GraphPad Prism software. 
 
Analysis of TCGA Gene Expression 
RNA-sequencing data of human CRC tumors was obtained from TCGA Colon Adenocarcinoma 
and Rectum Adenocarcinoma projects (25). WT cancers were defined as those with no activating 760 
mutations in KRAS, NRAS, or BRAF. Differential gene expression analysis was conducted by 
fitting a linear model to each gene with empirical Bayes smoothing of the standard error using the 
limma package in R (50,51). P values were controlled for multiple hypothesis testing using the 
Benjamini-Hochberg procedure. 
 765 
Analysis of TCGA Allele Frequencies 
Whole-exome sequencing data of the KRAS gene from the TCGA-COAD and TCGA-READ 
projects were downloaded from Genomic Data Commons and indexed using samtools (version 
1.9) (52). Read counts data were extracted using bcftools (version 1.9) mpileup and mutations were 
assigned using bcftools call and annotated with ANNOVAR (June 1, 2017) (52,53). Tumor sample 770 
purity data and genomic copy number data were downloaded from the PanCanAtlas Publications 
website (https://gdc.cancer.gov/about-data/publications/pancanatlas). Only samples with purity of 
at least 0.25 were used for further analysis. 
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 The copy number of the KRAS locus was adjusted for the purity of the sample (the fraction 
of the sample that are cancer cells). The measured copy number of the sample 𝑛+ is a linear 775 
combination of the copy number of the tumor cells 𝑛, and normal cells coincidentally extracted 𝑛-, and can expressed as 
   𝑛+ = 𝜌𝑛, + (1 − 𝜌)𝑛- (1) 
where 𝜌 is the purity of the tumor sample. Assuming the normal cells have a copy number of two, 
the copy number of the cancer cells can be solved for using Equation (2). 780 
  𝑛, = 34 (𝑛+ − 2(1 − 𝜌)) (2) 
 The copy number of the mutant KRAS allele was adjusted using the same formulation as 
described by (54). Briefly, the relationship between the number of reads of the mutant allele 𝑟7, 
the total number of sequencing reads of the locus 𝑟8, the copy number of the mutant allele 𝑛7, and 
the copy number of the locus 𝑛8 can be expressed as 785 
  9:9; = -:-;  (3) 
To account for the purity of the sample, 𝑛8 is replaced with the copy number of the sample 𝑛+ 
using equation (1), and the total number of sequencing reads is weighted by the purity 
  9:49; = -:4-<=(3>4)-? (4) 
which, assuming the normal cells have two copies of the wild type allele, solves to  790 
  𝑛7 = 9:49; (𝜌𝑛, − 2(1 − 𝑝)) (5) 
Negative final values were rounded to zero. Data were plotted using the ggplot2 package in R. 
 
Co-mutation Analysis 
  
 
35 
DNA sequence data for 224 colorectal tumors were obtained through cBioPortal for Cancer 795 
Genomics for TCGA colorectal carcinoma cohort. A one-sided Fisher’s Exact Test with 
Benjamini-Hochberg FDR correction was applied to assess the significance of co-occurring 
mutations with KRAS
 
and specific KRAS mutant alleles. Candidate KRAS allele co-mutation events 
were selected at a threshold of FDR q < 0.10. Co-mutation results were visualized using Cytoscape 
3.4.0 to create a statistical network with edges between genes and the KRAS allele node with which 800 
they significantly co-mutate.   
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FIGURE LEGENDS 
Figure 1. Biochemical characterization of mutant K-Ras. A, GDP dissociation curves. Each allele 
was evaluated +/- SOS1. B, Quantification of nucleotide exchange rates. The intrinsic exchange 
rate of K-Ras4BA146T is significantly higher than K-Ras4BWT and K-Ras4BG12D and it is further 985 
enhanced by SOS1. ** P < 0.01, unpaired t test; *** P < 0.01, unpaired t test.  C, SOS1:K-Ras4B 
interaction as measured by microscale thermophoresis. K-Ras4BA146T shows enhanced affinity 
toward SOS1 relative to K-Ras4BWT. The SOS1 construct includes the REM and CDC25 domains. 
D, Measurement of intrinsic GTP hydrolysis. K-Ras4BA146T and K-Ras4BG12D show slightly 
decreased hydrolysis relative to K-RasWT. Inset shows the curve for the hydrolysis reaction. **  P 990 
< 0.01, unpaired t test; ***  P < 0.01, unpaired t test. E, Measurement of p120GAP-induced GTP 
hydrolysis. GAP-induced hydrolysis is reduced for K-Ras4BG12D, but not by K-Ras4BA146T. Inset 
shows the curve for the hydrolysis reaction. * P < 0.05, unpaired t test; *** P < 0.01, unpaired t 
test. All assays were done in triplicate. 
 995 
Figure 2. Structure of K-Ras4BA146T. A, Comparison of K-Ras4BWT, K-Ras4BA146T, and K-
Ras4BG12D X-ray structures demonstrating extension of switch 1 (yellow) and increased flexibility 
of switch 2 (highlighted in green) in K-Ras4BA146T. B, 2Fo-Fc electron density contoured at 1.4σ 
for X-ray crystal structure of GDP:K-Ras4BA146T. GDP is colored by element and surrounding 
active site residues are labeled. The active site Mg from superimposed structure of GDP:K-1000 
Ras4BWT (4OBE) is also shown in magenta, demonstrating no density in this location for K-
Ras4BA146T. C, Regions of K-Ras4BA146T (highlighted in red) demonstrating increased deuterium 
exchange relative to WT, as measured by HDX-MS. D, SOS:H-Ras (PDB 1bkd) structure 
  
 
41 
demonstrates the SOS-RAS binding interface. Multiple regions of H-Ras would be covered by 
switch 1 in the closed form. 1005 
 
Figure 3. K-RasA146T exhibits tissue-specific effects on homeostasis. A, H&E images of the 
colonic epithelium from mice expressing different forms of mutant K-Ras. B, Quantification of 
epithelial crypt height as a function of colonic location in mice with indicated K-Ras genotypes. 
C, Box and whisker plot illustrating the quantification of average epithelial crypt height in the 1010 
colons of Fabp1-Cre mice expressing the indicated K-Ras allele. N=6 for WT, N=5 for A146T, 
and N=7 for G12D. * P < 0.05, Mann-Whitney U test; ** P < 0.01, Mann-Whitney U test. D, Box 
and whisker plot illustrating the quantification of average number of PH3-positive cells per crypt 
in the colons of Fabp1-Cre mice with indicated K-Ras genotypes. N=6 for WT, N=7 for A146T, 
and N=6 for G12D. * P < 0.05, Mann-Whitney U test; ** P < 0.01, Mann-Whitney U test. E, 1015 
White blood counts (WBC) from Mx1-Cre animals expressing different K-Ras alleles in 
hematopoietic cells. F, Hemoglobin (Hb) counts from Mx1-Cre animals expressing different K-
Ras alleles in hematopoietic cells. Error bars show mean ± s.e.m., and lines show modeled fixed 
effects from a mixed linear effects model. N=14 for WT, N=6 for A146T, and N=28 for G12D. G, 
Myeloid colony formation by bone marrow plated in methylcellulose with varying concentrations 1020 
of GM-CSF. Experiments were done in duplicate. H, Representative H&E images of pancreases 
from 8-week-old Pdx1-Cre mice expressing WT K-Ras, K-RasA146T, or K-RasG12D. Scale bar = 
100 µm in all panels. 
 
Figure 4. Allele effects in tumor models. A, Colonic tumors from Fabp1-Cre ; Apc2lox14/+ animals 1025 
expressing different K-Ras alleles. Top row: H&E, Bottom row: IHC for b-catenin. Later stage 
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tumors expressing K-RasA146T or K-RasG12D are not distinguishable histologically. B, Survival 
curves for Fabp1-Cre ; Apc2lox14/+ animals bearing colonic tumors. The penetrance of colonic 
tumors was 100% in all groups. C, Representative histology from pancreatic tumors expressing 
different mutant forms of K-Ras. D, Survival curves for Pdx1-Cre ; Tp53LSL-R270H/+ animals bearing 1030 
pancreatic tumors. All animals express Trp53R270H in the pancreas. Note that penetrance of PDAC 
was 100% in G12D, but only 75% in animals expressing A146T. Scale bar = 100 um in all panels. 
P values from survival curves calculated using Log-rank test.  
 
Figure 5. Global proteomics and phospho-proteomics analysis. A, Schematic of sample 1035 
preparation, processing, and data analysis workflow for mass spectrometry. B, GSEA results for 
KEGG pathway enrichment comparing A146T:WT (denoted by red line) and G12D:WT (denoted 
by blue line) using the colon total protein dataset. Each line in the heat map represents the 
normalized enrichment score (NES) for a single KEGG pathway. The expanded detail illustrates 
the rank metrics for proteins contributing to KEGG_NITROGEN_METABOLISM (commonly 1040 
up-regulated) and KEGG_CALCIUM_SIGNALING_PATHWAY (divergently regulated) 
enrichment. Each line in the heat map represents the rank metric for an individual protein in the 
corresponding KEGG pathway. C, GSEA results for KEGG pathway enrichment comparing 
A146T:WT and G12D:WT using the pancreas total protein dataset. The expanded detail illustrates 
the rank metrics for proteins contributing to KEGG_BASAL_TRANSCRIPTION_FACTORS 1045 
(commonly up-regulated), KEGG_NITROGEN_METABOLISM (commonly down-regulated), 
and KEGG_COMPLEMENT_AND_COAGULATION_CASCADES (divergently regulated). D, 
GSEA results for KEGG pathway enrichment comparing A146T:WT and G12D:WT using the 
spleen total protein dataset. The expanded detail illustrates the rank metrics for proteins 
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contributing to KEGG_CELL_CYCLE (commonly up-regulated) and 1050 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES (commonly down-regulated). 
E, Kinase activity inference results using the colon scaled phosphopeptide dataset for each K-Ras 
allele compared to WT. Each line in the heat map represents the normalized enrichment score 
(NES) for a single kinase. Erk2 and p90Rsk substrate enrichments are presented in the expanded 
detail. The asterisk (*) indicates Ser1120 of Sos1. F, Kinase activity inference results using the 1055 
pancreas scaled phosphopeptide dataset for each K-Ras allele compared to WT. Cdk2, Pkaca, and 
Ck2a1 substrate enrichments are presented in the expanded detail. G, Kinase activity inference 
results using the spleen scaled phosphopeptide dataset for each K-Ras allele compared to WT. 
Camk2a and Erk2 substrate enrichments are presented in the expanded detail. For panels B-G, 
NES values are shown for significantly enriched pathways or kinases (nominal P-value < 0.1 or 1060 
an FDR q-value < 0.25); insignificant pathways are shown with an NES value of 0. Those 
insignificant in both A146T:WT and G12D:WT are not shown.  Expanded detail compares protein 
rank metrics that contribute to the pathway enrichment; non-contributing substrates shown with a 
rank metric of 0 unless they do not contribute to either allele in which case they are not shown. 
 1065 
Figure 6. MAPK thresholds determine cellular behaviors in colon and small intestine. A, 
Representative western blots illustrating increased levels of p-Erk1/2 in the colons of Fabp1-Cre 
mice with different K-Ras genotypes. Each lane contains colon tissue lysate from one individual 
mouse. B, Box and whisker plots illustrating quantification of western blot analysis for p-Erk1/2 
For each signal, bands were normalized to the corresponding Gapdh intensity, and then normalized 1070 
values of the phosphorylated form were divided by the normalized values of total Erk1/2. N=6 
mice per genotype. * P < 0.05, Mann-Whitney U test; **  P < 0.01, Mann-Whitney U test. C, Box 
  
 
44 
and whisker plots illustrating the quantification of average number of PH3-positive cells per crypt 
following trametinib (Meki) treatment of Fabp1-Cre mice expressing different K-Ras alleles (0.25 
mg/kg, twice in 24 hours). N=5 for WT vehicle- and trametinib-treated, N=4 for A146T vehicle-1075 
treated, N=5 for A146T trametinib-treated, and N=5 for G12D vehicle- and trametinib-treated. * 
P < 0.05, Mann-Whitney U test; **  P < 0.01, Mann-Whitney U test. D, Representative western 
blot analysis of MAPK signaling components in the ilia of Fabp1-Cre mice with different K-Ras 
alleles. Each lane contains lysate from the distal ileum of an individual mouse. E, Box and whisker 
plots illustrating quantification of western blot analysis for p-Erk1/2. N=9 mice per genotype. * P 1080 
< 0.05, Mann-Whitney U test; ** P < 0.01, Mann-Whitney U test. F, Representative 
immunofluorescence of the ilia from Fabp1-Cre mice with indicated K-Ras genotypes for E-
cadherin (purple) and Lysozyme (green) following treatment with vehicle or trametinib (Meki, 1 
mg/kg, twice daily for four days). Lysozyme is a marker for Paneth cells. G, 
Immunohistochemistry for p-Erk1/2 in pancreases from Pdx1-Cre mice expressing mutant forms 1085 
of K-Ras. Insets contain high magnification images of pancreatic ducts. Scale bar = 50 µm in all 
panels. 






